Analyst picks & changes
(AMGN)
(GNE)
Cowen & Co. analyst Joyce Lonergan said the start of clinical trials of thrombopoietin to boost platelets underscores AMGN's development expertise — cloning of TPO was announced only eight
Gathering data...
(AMGN)
(GNE)
Cowen & Co. analyst Joyce Lonergan said the start of clinical trials of thrombopoietin to boost platelets underscores AMGN's development expertise — cloning of TPO was announced only eight